$125.72 -1.68 (%) Biomarin Pharmaceutical Inc - NASDAQ

May. 29, 2015 | 12:19 PM

Partner Headlines

  1. Sarepta Soars On New Hope For Muscular-Dystrophy Drug

    IBD | May. 20, 2015 | 11:45AM EST
  2. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD | May. 6, 2015 | 18:20PM EST
  3. BIOMARIN PHARMA

    IBD | Apr. 30, 2015 | 18:40PM EST
  4. BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

    Benzinga | Apr. 27, 2015 | 09:44AM EST
  5. J.P. Morgan's 3 Biotechnology Picks

    GuruFocus | Apr. 14, 2015 | 21:01PM EST
  6. What Evercore Is Watching At BioMarin Pharmaceutical

    Benzinga | Feb. 25, 2015 | 17:17PM EST
  7. BioMarin To Report Revenue In-line With Consensus, Wedbush Says

    Benzinga | Feb. 20, 2015 | 17:03PM EST
  8. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD | Feb. 19, 2015 | 16:59PM EST
  9. Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval

    Benzinga | Feb. 17, 2015 | 13:54PM EST
  10. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD | Feb. 10, 2015 | 10:30AM EST
  11. BIOMARIN PHARMA

    IBD | Jan. 21, 2015 | 18:42PM EST
  12. State Of The Union Lights Up Biotech

    Benzinga | Jan. 21, 2015 | 06:25AM EST
  13. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga | Jan. 16, 2015 | 15:34PM EST
  14. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical On Positive Preliminary BMN-190 Data

    Benzinga | Jan. 14, 2015 | 07:08AM EST
  15. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  16. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD | Jan. 9, 2015 | 15:42PM EST
  17. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD | Jan. 8, 2015 | 08:02AM EST
  18. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of A Potential Sale

    Benzinga | Jan. 6, 2015 | 12:34PM EST
  19. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD | Dec. 23, 2014 | 16:11PM EST
  20. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside

    Benzinga | Dec. 11, 2014 | 10:04AM EST
  21. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB

    Benzinga | Dec. 10, 2014 | 08:05AM EST
  22. BioMarin Will Report Breadth of Innovative Development Pipeline at Analyst, Investor Day

    Benzinga | Dec. 9, 2014 | 08:05AM EST
  23. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga | Nov. 24, 2014 | 20:20PM EST
  24. BioMarin buying Prosensa

    IBD | Nov. 24, 2014 | 18:43PM EST
  25. Trio Of Major Deals Disclosed

    IBD | Nov. 24, 2014 | 18:42PM EST
  26. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly Results; Tetraphase Pharmaceuticals Shares Spike Higher

    Benzinga | Nov. 24, 2014 | 15:26PM EST
  27. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters Shares Jump On Acquisition News

    Benzinga | Nov. 24, 2014 | 13:55PM EST
  28. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire Prosensa For $17.75/Share

    Benzinga | Nov. 24, 2014 | 11:54AM EST
  29. Benzinga's Volume Movers

    Benzinga | Nov. 24, 2014 | 10:28AM EST
  30. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD | Nov. 24, 2014 | 10:22AM EST
  31. Stocks Hitting 52-Week Highs

    Benzinga | Nov. 24, 2014 | 10:18AM EST
  32. Morning Market Movers

    Benzinga | Nov. 24, 2014 | 09:46AM EST
  33. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD | Nov. 24, 2014 | 09:19AM EST
  34. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga | Nov. 24, 2014 | 09:06AM EST
  35. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 24, 2014 | 08:10AM EST
  36. US Stock Futures Up Ahead Of Economic Data

    Benzinga | Nov. 24, 2014 | 07:20AM EST
  37. Stocks Hitting 52-Week Highs

    Benzinga | Nov. 10, 2014 | 10:17AM EST
  38. Benzinga's Top Upgrades

    Benzinga | Nov. 10, 2014 | 09:17AM EST
  39. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga | Oct. 21, 2014 | 20:11PM EST
  40. BioMarin Weathers The Storm

    Benzinga | Aug. 6, 2014 | 16:02PM EST
  41. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD | Aug. 5, 2014 | 18:30PM EST
  42. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD | Jun. 30, 2014 | 17:00PM EST
  43. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga | Jun. 9, 2014 | 09:41AM EST
  44. Benzinga's Top Upgrades

    Benzinga | Jun. 9, 2014 | 07:52AM EST
  45. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Mar. 12, 2014 | 10:01AM EST
  46. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, BMRN)

    Benzinga | Feb. 27, 2014 | 12:26PM EST
  47. Top Trending Tickers On StockTwits For February 18

    Benzinga | Feb. 18, 2014 | 10:22AM EST
  48. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Feb. 13, 2014 | 10:18AM EST
  49. You Can No Longer Ignore Biotech

    GuruFocus | Feb. 7, 2014 | 17:32PM EST
  50. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga | Jan. 29, 2014 | 11:44AM EST
Trading Center